KR950010892A - How to suppress uterine fibrosis - Google Patents

How to suppress uterine fibrosis Download PDF

Info

Publication number
KR950010892A
KR950010892A KR1019940026163A KR19940026163A KR950010892A KR 950010892 A KR950010892 A KR 950010892A KR 1019940026163 A KR1019940026163 A KR 1019940026163A KR 19940026163 A KR19940026163 A KR 19940026163A KR 950010892 A KR950010892 A KR 950010892A
Authority
KR
South Korea
Prior art keywords
compound
uterine fibrosis
chem
formula
pyrrolidino
Prior art date
Application number
KR1019940026163A
Other languages
Korean (ko)
Inventor
존 블랙 래리
조세프 컬리난 조지
윌리암 드라퍼 마이클
데이비드 존스 챨스
에드워드 세일러 데이비드
Original Assignee
피터 지. 스트링거
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피터 지. 스트링거, 일라이 릴리 앤드 캄파니 filed Critical 피터 지. 스트링거
Publication of KR950010892A publication Critical patent/KR950010892A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

A method of inhibiting uterine fibrosis comprising administering to a human or other mammal in need of treatment an effective amount of a compound having the formula <CHEM> Wherein R<1> and R<3> are independently hydrogen, -CH3, <CHEM> or <CHEM> wherein Ar is optionally substituted phenyl; wherein R<2> is selected from the group consisting of pyrrolidino and piperidino, a pharmaceutically acceptable salt or solvate thereof.

Description

자궁 섬유증 억제 방법How to suppress uterine fibrosis

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (4)

자궁 섬유증을 억제하는데 유용한 하기 일반식(I)와 화합물 또는 그의 약학적으로 허용가능한 염 또는 용매화물 :Formula (I) and a compound or a pharmaceutically acceptable salt or solvate thereof useful for inhibiting uterine fibrosis: 상기식에서, R1및 R3은 독립적으로 수소, -CH3, Wherein R 1 and R 3 are independently hydrogen, —CH 3 , (여기서, Ar은 선택적으로 치환된 페닐이다)이고; R2는 피롤리디노 및 피페리디노로 구성되는 그룹중에서 선택된다.Wherein Ar is optionally substituted phenyl; R 2 is selected from the group consisting of pyrrolidino and piperidino. 제1항에 있어서. 상기 화합물이 하이드로클로라이드 염 형태인 화합물.The method of claim 1. The compound is in the form of a hydrochloride salt. 제1항에 있어서, 예방적으로 투여하는 화합물.The compound of claim 1, which is administered prophylactically. 제1항에 있어서, 상기 화합물이 하기 구조식 또는 그의 하이드로클로라이드 염인 화합물 :The compound of claim 1, wherein the compound is of the formula ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019940026163A 1993-10-15 1994-10-13 How to suppress uterine fibrosis KR950010892A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8/138,642 1993-10-15
US08/138,642 US5457116A (en) 1993-10-15 1993-10-15 Methods of inhibiting uterine fibrosis

Publications (1)

Publication Number Publication Date
KR950010892A true KR950010892A (en) 1995-05-15

Family

ID=22482959

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940026163A KR950010892A (en) 1993-10-15 1994-10-13 How to suppress uterine fibrosis

Country Status (23)

Country Link
US (1) US5457116A (en)
EP (1) EP0651999B1 (en)
JP (1) JPH07188015A (en)
KR (1) KR950010892A (en)
CN (1) CN1058389C (en)
AT (1) ATE216582T1 (en)
AU (1) AU680042B2 (en)
CA (1) CA2118090A1 (en)
CZ (1) CZ287247B6 (en)
DE (1) DE69430465T2 (en)
DK (1) DK0651999T3 (en)
ES (1) ES2172525T3 (en)
HU (1) HUT71236A (en)
IL (1) IL111285A (en)
NO (1) NO943878L (en)
NZ (1) NZ264678A (en)
PH (1) PH31596A (en)
PT (1) PT651999E (en)
RU (1) RU2145851C1 (en)
SG (1) SG46324A1 (en)
TW (1) TW327601B (en)
UA (1) UA27883C2 (en)
ZA (1) ZA948031B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
USRE39049E1 (en) 1992-07-28 2006-03-28 Eli Lilly And Company Methods for inhibiting bone loss
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
USRE38968E1 (en) 1992-07-28 2006-02-07 Eli Lilly And Company Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
ATE406909T1 (en) 1993-05-13 2008-09-15 Poniard Pharmaceuticals Inc PREVENTION AND TREATMENT OF PATHOLOGIES ASSOCIATED WITH ABNORMAL PROLIFERATION OF SMOOTH MUSCLE CELLS
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
US5856340A (en) * 1995-02-28 1999-01-05 Eli Lilly And Company Method of treating estrogen dependent cancers
EP0833624B1 (en) 1995-06-07 2007-11-07 Poniard Pharmaceuticals, Inc. Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US5670523A (en) * 1996-01-29 1997-09-23 Eli Lilly And Company Methods of inhibiting musculoaponeurotic fibromatoses (desmoid tumors)
AU707675B2 (en) * 1996-01-29 1999-07-15 Eli Lilly And Company Methods of inhibiting musculoaponeurotic fibromatoses (desmoid tumors)
DE19604231A1 (en) * 1996-01-29 1997-07-31 Schering Ag Combined pharmaceutical preparation and its use for the treatment of gynecological disorders
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US5827876A (en) * 1996-04-09 1998-10-27 American Home Products Corporation Inhibition of bone loss by 3-(4-acrylamidobenzoyl) benzo b!-thiophenes
AU6959898A (en) * 1997-04-11 1998-11-11 David J. Grainger Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
CA2444787A1 (en) * 2001-05-22 2002-11-28 Eli Lilly And Company Tetrahydroquinolin derivatives for the inhibition of diseases associated with estrogen deprivation or with an aberrant physiological response to endogenous estrogen
ATE321754T1 (en) * 2001-05-22 2006-04-15 Lilly Co Eli 2-SUBSTITUTED 1,2,3,4-TETRAHYDROCINOLINES AND DERIVATIVES THEREOF, COMPOSITIONS AND METHODS
US20060106010A1 (en) * 2003-05-27 2006-05-18 Black Larry J Methods for inhibiting bone loss
US20080221163A1 (en) * 2005-01-18 2008-09-11 Jeffrey Alan Dodge Selective Estrogen Receptor Modulators

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
DE4122484A1 (en) * 1991-07-06 1993-01-07 Teves Gmbh Alfred CIRCUIT FOR DETECTING WHEEL SENSOR DEFECTS
JP3157882B2 (en) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 New benzothiophene derivatives
US5461065A (en) * 1993-10-15 1995-10-24 Eli Lilly And Company Methods for inhibiting endometriosis
US5457113A (en) * 1993-10-15 1995-10-10 Eli Lilly And Company Methods for inhibiting vascular smooth muscle cell proliferation and restinosis
US5418252A (en) * 1993-10-15 1995-05-23 Eli Lilly And Company Method for inhibiting cartilage degradation

Also Published As

Publication number Publication date
ES2172525T3 (en) 2002-10-01
RU94037235A (en) 1996-11-10
EP0651999B1 (en) 2002-04-24
NO943878D0 (en) 1994-10-13
CZ253894A3 (en) 1995-05-17
CZ287247B6 (en) 2000-10-11
EP0651999A1 (en) 1995-05-10
IL111285A0 (en) 1994-12-29
NO943878L (en) 1995-04-18
SG46324A1 (en) 1998-02-20
DE69430465T2 (en) 2002-10-31
CA2118090A1 (en) 1995-04-16
RU2145851C1 (en) 2000-02-27
US5457116A (en) 1995-10-10
AU680042B2 (en) 1997-07-17
HUT71236A (en) 1995-11-28
DK0651999T3 (en) 2002-06-17
DE69430465D1 (en) 2002-05-29
JPH07188015A (en) 1995-07-25
PH31596A (en) 1998-11-03
CN1058389C (en) 2000-11-15
NZ264678A (en) 1997-07-27
TW327601B (en) 1998-03-01
PT651999E (en) 2002-08-30
IL111285A (en) 1998-12-27
ZA948031B (en) 1996-04-15
ATE216582T1 (en) 2002-05-15
HU9402960D0 (en) 1995-02-28
AU7583494A (en) 1995-05-04
CN1107156A (en) 1995-08-23
UA27883C2 (en) 2000-10-16

Similar Documents

Publication Publication Date Title
KR950010893A (en) How to suppress endometriosis
KR950010892A (en) How to suppress uterine fibrosis
KR950016732A (en) How to suppress skin and vaginal atrophy
KR950010888A (en) How to inhibit smooth muscle cell proliferation and restenosis
KR950016738A (en) How to suppress Alzheimer&#39;s disease
KR950016745A (en) Method of treating physiological symptoms and composition for same
KR950010890A (en) Treatment of Menopause Syndrome
KR950016746A (en) Non-peptide Tachykinin Receptor Antagonists
KR950016744A (en) How to inhibit thrombin
KR950016725A (en) How to suppress pulmonary hypertension diseases
KR970706818A (en) METHODS OF INHIBITING CONDITIONS ASSOCIATED WITH NEUROPEPTIDE &amp;lt; RTI ID = 0.0 &amp;gt;
KR950016723A (en) How to suppress autoimmune diseases
KR950010889A (en) How to inhibit angiogenesis and angiogenic diseases
KR950016737A (en) Inhibition of symptoms of premenstrual syndrome / late luteal phase unpleasant disease
KR950016731A (en) How to suppress seborrhea and acne
KR950016726A (en) How to suppress dysfunctional uterine bleeding
KR950016730A (en) Methods of suppressing vasomotor symptoms and accompanying psychological disorders associated with postmenopausal syndrome
KR950010891A (en) How to treat resistant tumors
KR950010887A (en) How to inhibit cartilage degeneration
KR950016724A (en) How to increase libido in women after menopause
KR950016727A (en) How to increase thrombomodulin expression
KR950016742A (en) How to Suppress CNS Disease in Postmenopausal Women
KR950016735A (en) How to suppress Turner syndrome
KR950016733A (en) How to suppress ovarian dysfunction, puberty delay, or sexual attraction
KR950016734A (en) Inhibition of sexual prematurity

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application